Press Releases

• Sep 10, 2020 Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
• Jul 27, 2020 Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
• Jun 15, 2020 Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
• Jun 10, 2020 Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
• Jun 1, 2020 Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting
• May 28, 2020 Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
• May 14, 2020 Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
• Feb 10, 2020 Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
• Jan 27, 2020 Rezolute to Present at BIO CEO & Investor Conference 2020
• Dec 18, 2019 Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes